C. Steven Ernest
Eli Lilly and Company
17 Papers
129 Citations
C. Steven Ernest is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Prasugrel & Thienopyridine. The author has an hindex of 11, co-authored 17 publications. Previous affiliations of C. Steven Ernest include Uppsala University.
Chat about Author
Papers
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
Ying G. Li,Lan Ni,John T. Brandt,David S. Small,Christopher D. Payne,C. Steven Ernest,Shashank Rohatagi,Nagy A. Farid,Joseph A. Jakubowski,Kenneth J. Winters +9 more
TL;DR: This integrated analysis confirms the findings of earlier individual studies, that prasugrel achieves faster onset of greater extent and more consistent platelet inhibition compared to the approved and higher loading doses of clopidogrel.
60
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
C. Steven Ernest,David S. Small,Shashank Rohatagi,Daniel E. Salazar,Lars Wallentin,Kenneth J. Winters,Rebecca E. Wrishko +6 more
TL;DR: The clopidogrel PK model included dose as a covariate indicating that a significantly less-than-proportional increase in Clop-AM exposure is expected over the dose range of 75–600 mg, thus, the model-predicted PD response is lower than might be anticipated given an 8-fold difference in dose and lower than that typically achieved following prasugrel 60 mg LD.
57
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.
Nagy A. Farid,Christopher D. Payne,C. Steven Ernest,Y. Grace Li,Kenneth J. Winters,Daniel E. Salazar,David S. Small +6 more
TL;DR: The results of this open‐label, multiple‐dose, 2‐period, fixed‐sequence study assessed CYP2B6 inhibition by prasugrel using bupropion as a probe substrate, where its active metabolite, hydroxybupropion, is almost exclusively formed by CYP 2B6.
51
Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC).
Egbert F. Smit,Maurice Pérol,Martin Reck,Federico Cappuzzo,Paolo Bidoli,Roger B. Cohen,Ling Gao,C. Steven Ernest,Pablo Lee,Annamaria Zimmermann,David Ferry,Joseph Treat,Allen S. Melemed,Edward B. Garon +13 more
TL;DR: As RAM exposure increased, greater improvements were seen in OS and PFS, and a statistically significant correlation was also seen for RAM exposure and grade ≥ 3 febrile neutropenia and hypertension.
8
•Journal Article
Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38
Daniel E. Salazar,C. Steven Ernest,Rebecca E. Wrishko,Govinda Weerakkody,David S Small,Ying G. Li,Shashank Rhohatagi,Bruce E Dornseif,Lan Ni,Elliot M Antman,Stephen D. Wiviott,William L. Macias,Jeffrey S. Riesmeyer +12 more
TL;DR: In TRITON-TIMI 38, patients treated with prasugrel had a higher incidence of TIMI bleeding compared to treatment with clopidogrel, and was most evident in patients <60 kg or ≥75 year...
6